{"@id":"https://bioecon.ru/technology/induced-pluripotent-stem-cells-ipsc/","@type":"Technology","cluster":"regenerative-personalized","formats":{"html":"https://cn.bioecon.ru/technology/induced-pluripotent-stem-cells-ipsc/","json":"https://cn.bioecon.ru/api/v1/technology/induced-pluripotent-stem-cells-ipsc/index.json"},"id":"induced-pluripotent-stem-cells-ipsc","industries":["advanced-therapies"],"lang":"cn","links":{"industries":["https://bioecon.ru/industries/advanced-therapies/"],"suppliers":["https://bioecon.ru/companies/impacfat/","https://bioecon.ru/companies/esco-aster/","https://bioecon.ru/companies/kheiron-biotech/","https://bioecon.ru/companies/newlimit/","https://bioecon.ru/companies/integriculture/","https://bioecon.ru/companies/spiber-technologies-ab/","https://bioecon.ru/companies/simple-planet/","https://bioecon.ru/companies/orf-genetics/","https://bioecon.ru/companies/novartis/","https://bioecon.ru/companies/lonza-group/","https://bioecon.ru/companies/cryoport-systems/","https://bioecon.ru/companies/agc-biologics/"]},"maturity":null,"name":"诱导多能干细胞（iPSC）","regions":["ch","us","cn","eu"],"risk":"low","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-09-18","entity":"fate-therapeutics","kind":"vendor","urls":["https://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-announces-opening-its-cgmp-manufacturing","https://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-reports-third-quarter-2025-financial-results","https://ir.fatetherapeutics.com/node/13906/html","https://last10k.com/sec-filings/fate/0001193125-26-073699.htm","https://stocklight.com/stocks/us/nasdaq-fate/fate-therapeutics/annual-reports/nasdaq-fate-2026-10K-26682010.pdf","https://www.metatrader.com/en/symbols/nasdaq/fate/documents/234740-annual-report-fy2025"]},{"date":"2026-09-18","entity":"defined-bioscience","kind":"vendor","urls":["https://definedbioscience.com/blogs/news/defined-bioscience-launches-with-1-5m-sbir-from-the-nih-to-advance-stem-cell-media","https://definedbioscience.com/pages/app-notes/high-density-pluripotent-stem-cell-expansion-in-a-single-use-bioreactor-using-hi-def-s-8-tm-1","https://www.caplight.com/company/definedbioscience","https://www.inknowvation.com/sbir/companies/defined-bioscience-inc"]},{"date":"2026-09-18","entity":"cyprotex","kind":"vendor","urls":["https://www.evotec.com/news/evotec-completes-acquisition-of-cyprotex-plc","https://www.labcorp.com/education-events/articles/inside-preclinical-nams-innovation-qa-labcorp-experts-darren-kidd-and-jessica-palmer-devtox"]},{"date":"2026-11-22","entity":"Swiss Biotech Directory 2026","kind":"vendor","urls":["https://www.swissbiotech.org/directory/"]}],"stages":[{"n":1,"title":"供体活检"},{"n":2,"title":"重编程"},{"n":3,"title":"主库与限定培养"},{"n":4,"title":"分化"},{"n":5,"title":"检测或 GMP 批次"},{"n":6,"title":"监管放行"}],"summary":"将成体细胞重编程为胚芽样可扩增干细胞状态——即用 NK 细胞、限定培养基与人 iPSC 发育毒理学的平台。三行台账可溯；治疗应用归姊妹页面。","url":"/technology/induced-pluripotent-stem-cells-ipsc/","verified":"2026-09-18"}